14.35 USD
-0.62 (-4.14%)
14.63 USD
+0.28 (+1.95%)
Taking everything into account, RGNX scores 4 out of 10 in our fundamental rating. RGNX was compared to 530 industry peers in the Biotechnology industry. While RGNX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, RGNX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
RGNX had negative earnings in the past year.
RGNX had a negative operating cash flow in the past year.
RGNX had negative earnings in 4 of the past 5 years.
In the past 5 years RGNX reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of RGNX (-33.88%) is better than 63.77% of its industry peers.
Looking at the Return On Equity, with a value of -110.20%, RGNX is in line with its industry, outperforming 43.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.88% | ||
| ROE | -110.2% | ||
| ROIC | N/A |
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 87.18%, RGNX belongs to the top of the industry, outperforming 89.43% of the companies in the same industry.
RGNX's Gross Margin has declined in the last couple of years.
RGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
2. Health
2.1 Basic Checks
RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RGNX has been increased compared to 1 year ago.
RGNX has more shares outstanding than it did 5 years ago.
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
RGNX has an Altman-Z score of -1.82. This is a bad value and indicates that RGNX is not financially healthy and even has some risk of bankruptcy.
RGNX has a Altman-Z score (-1.82) which is in line with its industry peers.
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.82 |
ROIC/WACCN/A
WACC8.81%
2.3 Liquidity
A Current Ratio of 2.66 indicates that RGNX has no problem at all paying its short term obligations.
RGNX has a worse Current ratio (2.66) than 69.43% of its industry peers.
RGNX has a Quick Ratio of 2.66. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
RGNX has a Quick ratio of 2.66. This is in the lower half of the industry: RGNX underperforms 67.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.66 | ||
| Quick Ratio | 2.66 |
3. Growth
3.1 Past
RGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.32%, which is quite impressive.
Looking at the last year, RGNX shows a very strong growth in Revenue. The Revenue has grown by 91.30%.
Measured over the past years, RGNX shows a quite strong growth in Revenue. The Revenue has been growing by 18.81% on average per year.
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
Revenue 1Y (TTM)91.3%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%22.88%
3.2 Future
Based on estimates for the next years, RGNX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.45% on average per year.
RGNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.14% yearly.
EPS Next Y32.24%
EPS Next 2Y18.09%
EPS Next 3Y17.77%
EPS Next 5Y16.45%
Revenue Next Year109.62%
Revenue Next 2Y76.41%
Revenue Next 3Y58.45%
Revenue Next 5Y48.14%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RGNX. In the last year negative earnings were reported.
Also next year RGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RGNX's earnings are expected to grow with 17.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.09%
EPS Next 3Y17.77%
5. Dividend
5.1 Amount
No dividends for RGNX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
14.35
-0.62 (-4.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners82.82%
Inst Owner Change-2.14%
Ins Owners7.13%
Ins Owner Change-2.88%
Market Cap726.40M
Revenue(TTM)161.32M
Net Income(TTM)-177.91M
Analysts84.21
Price Target32.09 (123.62%)
Short Float %11.66%
Short Ratio8.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.56%
Min EPS beat(2)-22.99%
Max EPS beat(2)9.88%
EPS beat(4)2
Avg EPS beat(4)-18.77%
Min EPS beat(4)-75.63%
Max EPS beat(4)13.65%
EPS beat(8)3
Avg EPS beat(8)-8.87%
EPS beat(12)5
Avg EPS beat(12)-7.23%
EPS beat(16)6
Avg EPS beat(16)-6.26%
Revenue beat(2)1
Avg Revenue beat(2)-2.34%
Min Revenue beat(2)-25.51%
Max Revenue beat(2)20.83%
Revenue beat(4)1
Avg Revenue beat(4)-7.89%
Min Revenue beat(4)-25.51%
Max Revenue beat(4)20.83%
Revenue beat(8)2
Avg Revenue beat(8)-13.33%
Revenue beat(12)3
Avg Revenue beat(12)-16.53%
Revenue beat(16)5
Avg Revenue beat(16)-11.02%
PT rev (1m)0.74%
PT rev (3m)0.49%
EPS NQ rev (1m)-4.97%
EPS NQ rev (3m)-922.62%
EPS NY rev (1m)-19.57%
EPS NY rev (3m)-80.82%
Revenue NQ rev (1m)-6.93%
Revenue NQ rev (3m)-44.07%
Revenue NY rev (1m)-21.88%
Revenue NY rev (3m)-23.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.5 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.5 | ||
| P/tB | 4.5 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.47
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-2.1
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS3.19
BVpS3.19
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.88% | ||
| ROE | -110.2% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.18% | ||
| FCFM | N/A |
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 18.93% | ||
| Cap/Sales | 1.85% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.66 | ||
| Quick Ratio | 2.66 | ||
| Altman-Z | -1.82 |
F-Score5
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)103.5%
Cap/Depr(5y)301.57%
Cap/Sales(3y)13.73%
Cap/Sales(5y)15.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
EPS Next Y32.24%
EPS Next 2Y18.09%
EPS Next 3Y17.77%
EPS Next 5Y16.45%
Revenue 1Y (TTM)91.3%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%22.88%
Revenue Next Year109.62%
Revenue Next 2Y76.41%
Revenue Next 3Y58.45%
Revenue Next 5Y48.14%
EBIT growth 1Y36.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.6%
EBIT Next 3Y23.42%
EBIT Next 5Y18.75%
FCF growth 1Y54.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.4%
OCF growth 3YN/A
OCF growth 5YN/A
REGENXBIO INC / RGNX FAQ
What is the ChartMill fundamental rating of REGENXBIO INC (RGNX) stock?
ChartMill assigns a fundamental rating of 4 / 10 to RGNX.
Can you provide the valuation status for REGENXBIO INC?
ChartMill assigns a valuation rating of 0 / 10 to REGENXBIO INC (RGNX). This can be considered as Overvalued.
What is the profitability of RGNX stock?
REGENXBIO INC (RGNX) has a profitability rating of 2 / 10.
What is the expected EPS growth for REGENXBIO INC (RGNX) stock?
The Earnings per Share (EPS) of REGENXBIO INC (RGNX) is expected to grow by 32.24% in the next year.